 ISFIYA, Israel, June 30, 2021 PRNewswire -- Check-Cap Ltd. the Company or Check-Cap NASDAQ: CHEK, NASDAQ: CHEKZ, a clinical stage medical diagnostics company advancing the development of C-Scan, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer CRC, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Companys ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Companys ordinary shares in a registered direct offering. 